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The Prognosis of the HPV Infected Cervical Lesions after Followed-up for a Long Term
O Jou (Department of Gynecology and Obstetrics, Saitama Medical School, Moroyama, Iruma-gun, Saitama 
350-0495, Japan)
Objective: HPV infections are very common in women, only very few develop clinically relevant dysplastic lesions 
or even cancer. Some infected cases experienced spontaneous regression, and some showed persistent infection. 
On the other hand, cervical dysplasia that displays a certain persistent process from the normal to tumorigenic state 
in the tissues, is a precancerous lesion on the histopathological viewpoint. Unfortunately, long-term follow-up cases 
on HPV-infected uterocervixes are limited. In this study, patients with cervical dysplasia were monitored with the 
attempt of detecting the continuous changes in cervical lesions. Furthermore, treatments for the HPV-infected cases 
in progression group were attempted and progresses in these cases were observed. Materials and methods: We 
examined 573 women aged 16-81 who visited our Department of OB/Gyn between April 1992 and October 2002 for 
Papanicolaou Smear Testing and HPV examination. All the patients were divided into 3 groups. Progression group 
includes patients with developed process of cervical lesions, which were from smear ≦ Class II to mild dysplasia, 
or from mild to severe dysplasia, or from dysplasia to carcinoma in situ. Regression group consisted of patients 
with regression, or reducing from dysplasia to smear ≦ Class II or from severe to mild dysplasia. In the dysplasia 
cases, patients whose lesions persisted in one stage were classifi ed in persistence group. Results: Of 206 women 
who were followed-up for 2 years, 118(57.3%) were HPV-positive. Among these, the numbers of the three groups 
were 56(47.5%) in regression group, 35(29.6%) in persistence group, and 27(22.8%) in progression group. Among 
29 women infected with HPV-16, their distribution in the three groups were 5(17.2%), 12(41.4%) and 12(41.4%) 
respectively. Eighty-eight (42.7%) cases of 206 women were HPV-negative and their distribution in the three groups 
were 57(64.7%), 26(29.5%), and 5(5.7%), respectively. Of the post-operation cases, 16 were followed-up and their HPV 
persistencies were reevaluated. Within these 16 cases, 14 were turned out to be HPV-negative and got a smear ≦
Class II. Conclusion: The results confi rm an important pathogenic role of high-risk-types HPV infections in cervical 
dysplasia as well as in cervical cancers. After an effective treatment, HPV-positive cases have a strong tendency of 
negative conversion, and most of them have an HPV-negative report and normal histologycal fi ndings fi nally. 
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を細胞浮遊液（10 mM Tris-HCl pH 8.0, 150 mM NaCl, 
10 mM EDTA）1mlに懸濁して，処理するまで4℃で保
存した．DNA-蛋白複合体として存在するクロマチン
を可溶化するSDS (0.1％ )と蛋白分解酵素proteinase 
K （20 µg/ml ）を加え，懸濁し65 ℃，90 min処理
した．フェノール抽出を1回，フェノール/クロロホ
ルム抽出を1回施行し，蛋白質を変性させDNAから除
去した．得られたDNAはTE（1 mM Tris-HCl PH 8.0, 
1 mMEDTA pH 8.0）で溶解し，PCR template DNAと
して4℃で保存した．
HPVのE6，E7領域を下記のように設定したprimerを
用い，denature −95℃ 1 min，annealing −57℃ 1 min，
extension −72 ℃ 1 minに 設 定 し，35 cyclesでPCRを
行った．
(primer HPV E6U： 5’-TGTCAAAAACCGTTGTGTCC，
primer HPV E7U： 5’-GAGCTGTCGCTTAATTGCTC)14,15)
3，HPVの型別判定方法




length polymorphism），またはPerkin Elmer Applied 





































































％ )，型別不明が16例(11.0％ )であった（Table 4a）．
Table 1. 対象の臨床的背景
Table 2. HPV感染の有無と子宮頚部組織変化（（　）：％）
Table 3. 子宮頚部病変による HPVの頻度（（　）：％）
Table 4. 子宮頚部病変による HPV型別頻度（（　）：％）






















































Table 5. HPV陽性群と HPV陰性群の子宮頚部病変の消長
（（　）：％）
Table 6. 子宮頚部病変の消長（（　）：％）
Table 7. HPV16型の進行例 12例の内訳
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